

1. Seddon JA, Perez-Velez CM, **Schaaf HS**, Furin JJ, Marais BJ, Tebruegge M, Detjen A, Hesselning AC, Shah S, Adams LV, Starke JR, Swaminathan S, Becerra MC, on behalf of the Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Consensus statement on research definitions for drug-resistant tuberculosis in children. *J Ped Infect Dis Soc* 2013;2(2):100-109 [Epub 2013 Apr 10] DOI:10.1093/jpids/pit012.
2. Donald PR, Ahmed A, Burman W, Cotton MF, Graham SM, McIlleron H, Mendel C, Nachman S, **Schaaf HS**, Starke JR, Wingfield CR, Hesselning AC. Strategies for the clinical evaluation of new antituberculosis agents in children. *Int J Tuberc Lung Dis* 2013;17(6):794-9. doi: 10.5588/ijtld.12.0567
3. Seddon JA, Hesselning AC, Godfrey-Faussett P, Fielding K, **Schaaf HS**. Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study. *BMC Infect Dis* 2013;13:392 [Epub Aug 26 2013] doi:10.1186/1471-2334-13-392. <http://www.biomedcentral.com/1471-2334/13/392>
4. Rose PC, **Schaaf HS**, du Preez K, Seddon JA, Garcia-Prats AJ, Zimri K, Dunbar R, Swartz A, Hesselning AC. Completeness and accuracy of paediatric electronic drug-resistant tuberculosis registration in Cape Town, South Africa. *Public Health Action (PHA)* 2013; 3(3): 214–219.
5. Seddon JA, Hesselning AC, Finlayson H, Fielding K, Cox H, Hughes J, Godfrey-Faussett P, **Schaaf HS**. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort. *Clin Infect Dis* 2013;57(12):1676-84. doi: 10.1093/cid/cit655. Epub 2013 Sep 24. PMID 24065321
6. Seddon JA, Hesselning AC, Godfrey-Faussett P, **Schaaf HS**. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. *Thorax* 2014;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24. PMID 24064441
7. **Schaaf HS**, Cotton MF, Boon GPG, Jeena PM. Isoniazid preventive therapy in HIV-infected and uninfected children (0-14 years). *S Afr Med J* 2013;103(10):714-715. DOI:10.7196/SAMJ.7189
8. Van Toorn R, **Schaaf HS**, Laubscher JA, Elsland SL, Donald PR, Schoeman JF. Short intensified treatment in children with drug-susceptible tuberculous meningitis. *Pediatr Infect Dis J* 2014;33(3):248-52. doi:10.1097/INF.0000000000000065. [Epub 2013 Oct 28] PMID:24168978
9. Garcia-Prats AJ, Rose PC, Hesselning AC, **Schaaf HS**. Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations. *Tuberculosis (Edinb)* 2014;94:93-104. doi: 10.1016/j.tube.2013.10.003. [Epub ahead of print]
10. Zvada, SP, Denti P, Donald PR, **Schaaf HS**, Thee S, Seddon JA, Seifart HI, Smith PJ, McIlleron HM, Simonsson USH. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis, *in silico* evaluation of currently recommended doses. *J Antimicrob Chemother* 2014;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31. PMID 24486870
11. Kibleur Y, Brochart H, **Schaaf HS**, Diacon AH, Donald PR. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis. *Clin Drug Investig* 2014;34(4):269-276 DOI 10.1007/s40261-014-0172-7 [Epub ahead of print Feb 1.] PMID 24488376
12. Bekker A, **Schaaf HS**, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesselning AC. The pharmacokinetics of isoniazid in low birth weight and premature infants.

- Antimicrob Agents Chemother 2014; 58(4):2229-34. doi: 10.1128/AAC.01532-13. [Epub ahead of print 2014 Feb 3] PMID 24492365.
13. Bekker A, Slogrove A, **Schaaf HS**, Du Preez K, Hesselning AC. Determinants of tuberculosis therapy completion amongst newborns in a high-burden setting. *Int J Tuberc Lung Dis* 2014; 18(3):335–340. doi: 10.5588/ijtld.13.0506. PMID 24670572.
 14. Thee S, Garcia-Prats AJ, McIlleron HM, Wiesner L, Castel S, Norman J, Draper HR, van der Merwe PL, Hesselning AC, **Schaaf HS**. Pharmacokinetics of ofloxacin and levofloxacin for the prevention and treatment of multidrug-resistant tuberculosis in children. *Antimicrob Agents Chemother* 2014;58(5):2948-51. doi: 10.1128/AAC.02755-13. Epub 2014 Feb 18. PMID 24550337
 15. **Schaaf HS**. Multidrug-resistant tuberculosis in children. *Paediatric Focus* 2014;5(1):8-10.
 16. Marais BJ, **Schaaf HS**, Graham SM. Child health and tuberculosis. (Commentary) *Lancet Respir Dis* 2014; 2(4):254-256. doi: 10.1016/S2213-2600(14)70009-8. Epub 2014 Mar 24. PMID 24717618
 17. Garcia-Prats AJ, Willemse M, Seifart HI, Jordaan AM, Werely CJ, Donald PR, **Schaaf HS**. Acquired drug-resistance during inadequate therapy in a young child with tuberculosis. *Pediatr Infect Dis J* 2014;33(8):883-885. [Epub ahead of print April 18]
 18. **Schaaf HS**, Garcia-Prats AJ, Hesselning AC, Seddon JA. Managing multidrug resistant tuberculosis in children - Review of recent developments. *Curr Opin Infect Dis* 2014;27(3):211–219. DOI:10.1097/QCO.0000000000000062. 2014 April 18 [Epub ahead of print]. PMID 24751893
 19. Van Toorn R, **Schaaf HS**, Solomons R, Laubscher JA, Schoeman JF. The value of Transcranial doppler imaging in children with tuberculous meningitis. *Child Nerv Syst* 2014;30(10):1711-6. doi: 10.1007/s00381-014-2435-2. Epub 2014 May 15.
 20. Seddon JA, Padayachee T, du Plessis AM, Goussard P, **Schaaf HS**, Lombard C, Gie RP. Teaching chest X-ray reading for child tuberculosis suspects. *Int J Tuberc Lung Dis* 2014;18(7):763–769. <http://dx.doi.org/10.5588/ijtld.13.0892>
 21. **Schaaf HS**, Hesselning AC, Rautenbach C, Seddon JA. Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic? *Int J Tuberc Lung Dis* 2014;18(7):770-773. <http://dx.doi.org/10.5588/ijtld.13.0069>
 22. Reichman LB, **Schaaf HS**, Pontali E, Migliori GB. A new paradigm for multidrug-resistant tuberculosis? (Editorial) *Int J Tuberc Lung Dis* 2014;18(8):884. <http://dx.doi.org/10.5588/ijtld.14.0347>
 23. Marais BJ, **Schaaf HS**. Tuberculosis in children. *Cold Spring Harb Perspect Med* 2014;4(9):a017855. doi: 10.1101/cshperspect.a017855.
 24. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; on behalf of The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB; on behalf of The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug- and extensive drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. *Clin Infect Dis* 2014 59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5 (**Schaaf HS** as collaborator co-author)

25. Franck C, Seddon JA, Hesselning AC, **Schaaf HS**, Skinner D, Reynolds L. Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. *BMC Infect Dis* 2014;14:426. <http://www.biomedcentral.com/1471-2334/14/426>
26. Garcia-Prats AJ, Zimri K, Mramba Z, **Schaaf HS**, Hesselning AC. Children exposed to multidrug-resistant tuberculosis at a homebased day care centre: a contact investigation. *Int J Tuberc Lung Dis* 2014;18(11):1292-1298. <http://dx.doi.org/10.5588/ijtld.13.0872>
27. Seddon JA, Godfrey-Faussett P, Hesselning AC, **Schaaf HS**, Enarson DA. Preventive therapy for child contacts of tuberculosis in high-burden settings: cause for debate? *S Afr J Infect Dis (SAJID)* 2014;29(3):120-124.
28. Alsleben N, Garcia-Prats AJ, Hesselning AC, Willemsse M, Donald PR, **Schaaf HS**. Successful treatment of a child with extensively drug-resistant tuberculous meningitis. *J Pediatr Infect Dis Soc* 2015; 4(3):e41-e44. doi: 10.1093/jpids/piu120 Published online: December 23, 2014
29. Thee S, Garcia-Prats AJ, Draper HR, McIlleron HM, Wiesner L, Castel S, **Schaaf HS**, Hesselning AC. The pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. *Clin Infect Dis* 2015;60(4):549-56. doi: 10.1093/cid/ciu868. Epub 2014 Oct 30.
30. Van Toorn R, du Plessis A, **Schaaf HS**, Buys H, Hewlett RH, Schoeman JF. Clinico-radiological response of neurological tuberculous mass lesions in children treated with thalidomide. *Pediatr Infect Dis J* 2015;34(2):214–218. doi: 10.1097/INF.0000000000000539
31. Mandalakas AM, Kirchner HL, Walzl G, Gie RP, **Schaaf HS**, Cotton MF, Grewal H, Hesselning AC. Optimizing the detection of TB infection in children in a high TB-HIV burden setting. *Am J Respir Crit Care Med* 2015;191(7):820-30. doi: 10.1164/rccm.201406-1165OC. PMID:25622087
32. Wiseman CA, Mandalakas AM, Kirchner HL, Gie RP, **Schaaf HS**, Walters E, Hesselning AC. Novel application of NIH case definitions in a paediatric tuberculosis contact investigation study. *Int J Tuberc Lung Dis* 2015;19(4):446-453. <http://dx.doi.org/10.5588/ijtld.14.0585>
33. Thee S, Garcia-Prats AJ, Donald PR, Hesselning AC, **Schaaf HS**. Fluoroquinolones for the treatment of tuberculosis in children. *Tuberculosis (Edinb)* 2015;95(3):229-45. doi: 10.1016/j.tube.2015.02.037. [Epub ahead of print]
34. Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesselning A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, **Schaaf HS**, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. *Lancet Infect Dis* 2015;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6
35. **Schaaf HS**, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. *Clin Pharmacol Ther.* 2015;98(3):252-65. doi: 10.1002/cpt.164. [Epub ahead of print]
36. Garcia-Prats AJ, Draper HR, Thee S, Dooley K, McIlleron HM, Seddon JA, Wiesner L, **Schaaf HS**, Hesselning AC. The pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. *Antimicrob Agents Chemother* 2015;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.

37. Thee S, Garcia-Prats AJ, Donald PR, Hesselning AC, **Schaaf HS**. A review of the use of ethionamide and prothionamide in childhood tuberculosis. *Tuberculosis (Edinb)*. 2016;97:126-136. doi: 10.1016/j.tube.2015.09.007.
38. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB” (including **Schaaf HS**); The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Surgery as an adjunctive treatment for multi-drug resistant tuberculosis: an individual patient data meta-analysis. *Clin Infect Dis* 2016;62(7):887-895. doi: 10.1093/cid/ciw002. [Epub 2016 Jan 12]
39. Bekker A, **Schaaf HS**, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesselning AC. The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines. *Antimicrob Agents Chemother*. 2016;60(4):2171-2179. doi: 10.1128/AAC.02600-15.
40. Van der Laan, **Schaaf HS**, Solomons R, Willemse M, Mohamed N, Baboolal SO, Hesselning AC, van Toorn R, Garcia-Prats AJ. Probable Levofloxacin-Associated Secondary Intracranial Hypertension in a Child with Multidrug-Resistant Tuberculosis. *Pediatr Infect Dis J*. 2016;35(6):706-708. doi: 10.1097/INF.0000000000001137.
41. **Schaaf HS**, Garcia-Prats AJ. Multidrug-resistant tuberculosis in children: recent developments in diagnosis, treatment and prevention. *Curr Pediatr Rep* 2016;4(3):53–62. doi:10.1007/s40124-016-0100-9.
42. **Schaaf HS**, Thee S, van der Laan L, Hesselning AC, Garcia-Prats AJ. Adverse effects of second-line antituberculosis drugs in children. *Expert Opin Drug Saf* 2016;15(10):1369-1381. doi: 10.1080/14740338.2016.1216544. PMID:27458876. [Epub ahead of print Jul 26]
43. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O’Brien R, Peloquin CA, Raftery A, Saukkonen J, **Schaaf HS**, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis*. 2016;63(7):e147-95. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10. PMID:27516382
44. Garcia-Prats AJ, **Schaaf HS**, Hesselning AC. The safety and tolerability of the second-line injectable antituberculosis drugs in children. *Expert Opinion Drug Safety* 2016;15(11):1491-1500. [Epub ahead of print Aug 22] DOI: 10.1080/14740338.2016.1223623.
45. **Schaaf HS**, Garcia-Prats AJ, du Preez K, Rautenbach C, Hesselning AC. Surveillance provides insight into the evolving epidemiology and spectrum of mycobacterial disease in children. *Int J Tuberc Lung Dis* 2016;20(9):1249-1256. doi: 10.5588/ijtld.15.0051.
46. Fox GJ, **Schaaf HS**, Mandalakas A, Chiappini E, Zumla A, Marais BJ. Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. *Clin Microbiol Infect* 2017;23:147-153. doi: 10.1016/j.cmi.2016.08.024. (Epub ahead of print 2016 Aug 31. pii: S1198-743X(16)30363-9.)

47. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, **Schaaf HS**, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63(7):853-67. doi: 10.1093/cid/ciw566.
48. Garcia-Prats AJ, du Plessis L, Draper HR, Burger A, Seddon JA, Zimri K, Hesselning AC, **Schaaf HS**. Outcomes of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children. *Int J Tuberc Lung Dis* 2016;20(11):1469-1476. <http://dx.doi.org/10.5588/ijtld.16.0293>
49. Dheda K, Chang KC, Guglielmetti L, Furin J, **Schaaf HS**, Chesov D, Esmail A, Lange C. Clinical management of adults and children with MDR and XDR-TB. *Clin Microbiol Infect* 2017 Mar;23(3):131-140. doi: 10.1016/j.cmi.2016.10.008. Epub 2016 Oct 15. Review. PMID:27756712
50. Bekker A, **Schaaf HS**, Draper HR, Kriel M, Hesselning AC. Tuberculosis disease during pregnancy and treatment outcomes in HIV-infected and uninfected women at a referral hospital in Cape Town. *PLoS One*. 2016 Nov 3;11(11):e0164249. doi: 10.1371/journal.pone.0164249. eCollection 2016
51. Seddon JA, **Schaaf HS**. Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. *Pneumonia (Nathan)* 2016;8:20. DOI 10.1186/s41479-016-0019-5
52. Haraus EP, Garcia-Prats AJ, Seddon JA, **Schaaf HS**, Hesselning AC, Achar J, Bernheimer J, Cruz A, D'Ambrosio L, Detjen A, Graham SM, Hughes J, Jonckheere S, Marais BJ, Battista Migliori G, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J; Sentinel Project on Pediatric Drug-Resistant Tuberculosis. New/repurposed drugs for pediatric multidrug-resistant tuberculosis: practice-based recommendations. *Am J Respir Crit Care Med*. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI. Review. PMID:27854508
53. McAnaw SE, Hesselning AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, **Schaaf HS**, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. *Int J Infect Dis*. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. Review. PMID:27955992
54. Walters E, van der Zalm MM, Palmer M, Bosch C, Demers AM, Draper HR, Goussard P, **Schaaf HS**, Friedrich SO, Whitelaw A, Warren R, Gie RP, Hesselning AC. Xpert MTB/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease. *Pediatr Infect Dis J*. 2017 Sep;36(9):837-843. doi: 10.1097/INF.0000000000001563. PMID:28151842
55. Jaganath D, **Schaaf HS**, Donald PR. The mutant prevention concentration in the chemotherapy of childhood tuberculosis. *J Antimicrob Chemother*. 2017 Jul 1;72(7):1848-1857. doi: 10.1093/jac/dkx051. PMID:28333284
56. Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemand M, Hesselning AC, **Schaaf HS**. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. *Expert Opin Pharmacother*. 2017

- Apr;18(6):589-598. doi: 10.1080/14656566.2017.1309023. Epub 2017 Mar 27. Review. PMID: 28346018
57. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell E, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, van Rie A, Siu GKH, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, **Schaaf HS**, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesselning AC, Nuermberger E, McIlleron H, Fennelly KP, Goemare E, Jaramillo E, Low M, Moran C, Padayatchi N, Warren R. The epidemiology, pathogenesis, transmission, diagnosis and management of MDR-TB, XDR-TB, and incurable cases of TB. *Lancet Respir Dis* 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.
 58. Golla V, Snow K, Mandalakas AM, **Schaaf HS**, Du Preez K, Hesselning AC, Seddon JA. The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study. *BMC Infect Dis*. 2017 Aug 29;17(1):593. doi: 10.1186/s12879-017-2668-2. PMID:28851285
 59. Obihara NJ, Walters E, Lawrenson J, Garcia-Prats AJ, Hesselning AC, **Schaaf HS**. Tuberculous pericardial effusions in children. *J Pediatric Infect Dis Soc*. 2018;7(4):346-349. doi: 10.1093/jpids/pix087.
 60. Van der Laan LE, Garcia-Prats AJ, **Schaaf HS**, Tikiso T, Wiesner L, de Kock M, Winckler J, Norman J, McIlleron H, Denti P, Hesselning AC. pharmacokinetics and drug-drug interactions of lopinavir-ritonavir administered with first- and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2). pii: e00420-17. doi: 10.1128/AAC.00420-17. Print 2018 Feb. PMID: 29133558
 61. Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, **Schaaf HS**, Hesselning AC. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb. PMID: 29133560
 62. **Schaaf HS**, Garcia-Prats AJ, McKenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. *Expert Rev Clin Pharmacol*. 2018 Mar;11(3):233-244. doi: 10.1080/17512433.2018.1421067. Epub 2017 Dec 27. Review. PMID:29280409
 63. García-Basteiro AL, **Schaaf HS**, Diel R, Migliori GB. Adolescents and young adults: a neglected population group for tuberculosis surveillance. *Eur Respir J*. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. Print 2018 Feb.
 64. Garcia-Prats AJ, Rose PC, Draper HR, Seddon JA, Norman J, McIlleron HM, Hesselning AC, **Schaaf HS**. Effect of co-administration of lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial. *Pediatr Infect Dis J*. 2018;37(12):1199-1203. doi:10.1097/INF.0000000000001983. Publish ahead of print, 14 Mar 2018.
 65. Du Preez K, **Schaaf HS**, Dunbar R, Walters E, Swartz A, Solomons R, Hesselning AC. Complementary surveillance strategies are needed to better characterise the epidemiology, are pathways and treatment outcomes of tuberculosis in children. *BMC Public Health* 2018;18:397. <https://doi.org/10.1186/s12889-018-5252-9>

66. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien J, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh W, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, **Schaaf HS**, Skrahina A, van Soolingen D, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang J, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med* 2018;6(4):265-275.
67. Byamungu LN, du Preez K, Walters E, Nachegea JB, **Schaaf HS**. Timing of HIV diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa. *Int J Tuberc Lung Dis* 2018;22(5):488–495
DOI: <https://doi.org/10.5588/ijtld.17.0613>
68. Garcia-Prats AJ, Svensson EM, Weld ED, **Schaaf HS**, Hesselning AC. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. *Int J Tuberc Lung Dis* 2018;22(5; Suppl 1):15-23. doi: 10.5588/ijtld.17.0355
69. Seddon JA, Weld ED, **Schaaf HS**, Garcia-Prats AJ, Kim S, Hesselning AC. Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done? *Int J Tuberc Lung Dis*. 2018;22(5;Suppl 1):24-33. doi: 10.5588/ijtld.17.0359
70. Garcia-Prats AJ, Draper HR, Finlayson H, Winckler J, Burger A, Fourie B, Thee S, Hesselning AC, **Schaaf HS**. Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. *Clin Infect Dis*. 2018 Nov 13;67(11):1777-1780. doi: 10.1093/cid/ciy416.
71. Haraus EP, Garcia-Prats AJ, Law S, **Schaaf HS**, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesselning AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. *PLoS Med*. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591.
72. Frigati L, Bekker A, Stroebele S, Goussard P, **Schaaf HS**. Culture-confirmed tuberculosis in South African infants younger than 3 months of age: clinical presentation and management of respiratory complications. *Pediatr Infect Dis J* 2018 [Ahead of print 27 Aug 2018] doi: 10.1097/INF.0000000000002163
73. Seddon JA, **Schaaf HS**, Marais BJ, McKenna L, Garcia-Prats AJ, Hesselning AC, Hughes J, Howell P, Detjen A, Amanullah F, Singh U, Master I, Perez-Velez CM, Misra N, Becerra MC, Furin JJ. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. *Lancet Respir Med* 2018;6(9):662-664. doi: 10.1016/S2213-2600(18)30329-1. PMID: 30191832

74. Van Elsland SL, van Dongen SI, Bosmans JE, **Schaaf HS**, van Toorn R, van Furth AM. Cost-effectiveness of home-based versus in-hospital treatment of paediatric tuberculous meningitis. *Int J Tuberc Lung Dis* 2018;22(10):1188–1195.
75. Mann TN, **Schaaf HS**, Dunn RN, Dix-Peek S, du Preez K, Lamberts RP, du Toit J, Davis JH. Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa: 4 year burden and trend. *Epidemiology and Infection* 1–9. <https://doi.org/10.1017/S0950268818002649>
76. Walters E, van der Zalm MM, Demers AM, Whitelaw A, Palmer M, Bosch C, Draper HR, **Schaaf HS**, Goussard P, Lombard CJ, Gie RP, Hesselning AC. Specimen pooling as a diagnostic strategy for microbiologic confirmation in children with intrathoracic tuberculosis. *Pediatr Infect Dis J* 2018 Nov 9. doi: 10.1097/INF.0000000000002240. [Epub ahead of print]
77. Purchase S, Garcia-Prats AJ, Wademan D, Hoddinott G, de Koker P, Draper H, Seddon JA, **Schaaf HS**, Hesselning AC. Acceptability of a novel levofloxacin dispersible tablet formulation in young children exposed to multidrug-resistant tuberculosis. *Pediatr Infect Dis J* 2018 Dec 13. doi: 10.1097/INF.0000000000002268. [Epub ahead of print]
78. Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, Crook AM, Owen-Powell E, Thomason M, Turkova A, Gibb DM, Fairlie L, Martinson N, **Schaaf HS**, Hesselning AC. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). *Trials* 2018;19:693. <https://doi.org/10.1186/s13063-018-3070-0>
79. Du Preez K, Seddon JA, **Schaaf HS**, Hesselning AC, Starke JR, Osman M, Lombard CJ, Solomons R. Global shortages of BCG vaccine and tuberculous meningitis in children. *Lancet Global Health* 2019;7:e28-e29.
80. **Schaaf HS**. Diagnosis and management of multidrug-resistant tuberculosis in children: a practical approach. *Indian J Pediatr.* 2019 Jan 17. doi: 10.1007/s12098-018-02846-8. [Epub ahead of print]
81. Garcia-Prats AJ, Purchase SE, Osman M, Draper HR, **Schaaf HS**, Wiesner L, Denti P, Hesselning AC. Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure. *Antimicrob Agents Chemother* 2019 Jan 22. pii: AAC.01865-18. doi: 10.1128/AAC.01865-18. [Epub ahead of print] PMID:306704